X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-04-30 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.03 | +3,349 | 329,648 | +1% | +$6,793 | |||||
2025-04-29 | ABP | Abpro Holdings, Inc. | Suk Jin Wook (Miles) | CEO, COB | P - Purchase | $0.25 | +4,325 | 130,277 | +3% | +$1,081 | ||||||
| M | 2025-04-28 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $3.02 | -12,103 | 390,081 | -3% | -$36,541 | |||||
| M | 2025-04-28 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $3.07 | -19,191 | 355,376 | -5% | -$58,849 | |||||
| M | 2025-04-28 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $3.02 | -31,562 | 583,490 | -5% | -$95,381 | |||||
| M | 2025-04-28 | RLAY | Relay Therapeutics, Inc. | Adams Brian | GC | S - Sale | $3.02 | -14,587 | 391,385 | -4% | -$44,040 | |||||
2025-04-28 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.22 | +1,001 | 326,299 | 0% | +$2,222 | ||||||
| D | 2025-04-29 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $64.20 | -1,500 | 0 | -100% | -$96,300 | |||||
| D | 2025-04-25 | SRRK | Scholar Rock Holding Corp | Sacco Tracey | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $32.83 | -5,000 | 71,750 | -7% | -$164,131 | |||||
| D | 2025-04-28 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $30.76 | -1,000 | 0 | -100% | -$30,760 | |||||
| D | 2025-04-23 | BCDA | Biocardia, Inc. | Krasno Richard M | Dir | P - Purchase | $1.91 | +13,123 | 16,268 | +417% | +$24,999 | |||||
2025-04-28 | HALO | Halozyme Therapeutics, Inc. | Henderson Jeffrey William | Dir | S - Sale | $60.37 | -4,497 | 28,611 | -14% | -$271,467 | ||||||
| AM | 2025-03-26 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | P - Purchase | $5.11 | +37,000 | 2,864,561 | +1% | +$188,931 | |||||
| M | 2025-03-26 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | P - Purchase | $5.11 | +37,000 | 2,864,561 | +1% | +$188,931 | |||||
| D | 2025-04-23 | BCDA | Biocardia, Inc. | McClung David | CFO | P - Purchase | $1.91 | +13,123 | 43,131 | +44% | +$24,999 | |||||
| D | 2025-04-23 | BCDA | Biocardia, Inc. | Facteau Bill | Dir | P - Purchase | $1.91 | +13,123 | 13,123 | New | +$24,999 | |||||
| D | 2025-04-23 | BCDA | Biocardia, Inc. | Blank Andrew Scott | Dir | P - Purchase | $1.91 | +131,233 | 275,769 | +91% | +$249,999 | |||||
| D | 2025-04-23 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $1.91 | +104,986 | 243,586 | +76% | +$199,998 | |||||
| D | 2025-04-23 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.91 | +26,246 | 138,966 | +23% | +$49,999 | |||||
| M | 2025-04-23 | ABP | Abpro Holdings, Inc. | Suk Jin Wook (Miles) | CEO, COB | P - Purchase | $0.33 | +34,002 | 125,902 | +37% | +$11,113 | |||||
2025-04-23 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $14.79 | -1,925 | 209,243 | -1% | -$28,471 | ||||||
2025-04-23 | IMVT | Immunovant, Inc. | Geffner Michael | Chief Medical Officer | S - Sale | $14.79 | -2,349 | 225,370 | -1% | -$34,742 | ||||||
2025-04-23 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.05 | +175 | 325,298 | 0% | +$359 | ||||||
2025-04-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $40.00 | -2,058 | 265,460 | -1% | -$82,310 | ||||||
| M | 2025-04-22 | PASG | Passage Bio, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $0.33 | -235,572 | 6,650,000 | -3% | -$78,731 | |||||
2025-04-22 | PROK | Prokidney Corp. | Control Empresarial De Capitales S.A. De C.V. | Add'l Rep. Persons-see Ex.99-1, 10% | P - Purchase | $0.71 | +387,393 | 73,842,723 | +1% | +$276,366 | ||||||
2025-04-23 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $2.97 | -61,422 | 1,708,570 | -3% | -$182,423 | ||||||
| M | 2025-04-22 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | P - Purchase | $3.00 | +350,000 | 3,249,326 | +12% | +$1,048,950 | |||||
2025-04-21 | ALLO | Allogene Therapeutics, Inc. | Yoshiyama Annie | SVP, Finance | S - Sale | $1.41 | -9,601 | 130,663 | -7% | -$13,537 | ||||||
| D | 2025-04-21 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $7.28 | -997 | 8,819 | -10% | -$7,261 | |||||
| D | 2025-04-21 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $7.28 | -1,244 | 45,453 | -3% | -$9,060 | |||||
2025-04-11 | AIM | Aim Immunotech Inc. | Mitchell William M | Dir | P - Purchase | $0.03 | +196,851 | 522,103 | +61% | +$5,000 | ||||||
2025-04-11 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.03 | +1,968,504 | 3,867,533 | +104% | +$50,000 | ||||||
2025-04-11 | AIM | Aim Immunotech Inc. | Kellner Ted D | Dir | P - Purchase | $0.03 | +1,968,504 | 3,720,504 | +112% | +$50,000 | ||||||
2025-04-21 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.05 | +36 | 325,123 | 0% | +$74 | ||||||
2025-04-22 | MGTX | Meiragtx Holdings Plc | Giroux Richard | CFO, COO | S - Sale | $6.00 | -24,000 | 972,646 | -2% | -$144,000 | ||||||
2025-04-17 | PROK | Prokidney Corp. | Control Empresarial De Capitales S.A. De C.V. | Add'l Rep. Persons-see Ex.99-1, 10% | P - Purchase | $0.75 | +25,000 | 73,455,330 | 0% | +$18,690 | ||||||
2025-04-16 | PROK | Prokidney Corp. | Control Empresarial De Capitales S.A. De C.V. | Add'l Rep. Persons-see Ex.99-1, 10% | P - Purchase | $0.75 | +100,000 | 73,430,330 | 0% | +$74,820 | ||||||
2025-04-15 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.14 | +100 | 112,720 | 0% | +$214 | ||||||
| M | 2025-04-15 | PASG | Passage Bio, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $0.33 | -149,054 | 6,885,572 | -2% | -$49,704 | |||||
2025-04-16 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $14.89 | -2,993 | 396,774 | -1% | -$44,566 | ||||||
2025-04-16 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $14.89 | -8,321 | 1,178,191 | -1% | -$123,900 | ||||||
| D | 2025-04-15 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $21.46 | -21,000 | 3,780,233 | -1% | -$450,660 | |||||
2025-04-16 | AURA | Aura Biosciences, Inc. | Elazzouzi Amy | SVP, Finance | S - Sale | $5.49 | -897 | 81,381 | -1% | -$4,925 | ||||||
2025-04-16 | AURA | Aura Biosciences, Inc. | Kilroy Conor | See Remarks | S - Sale | $5.49 | -7,162 | 179,313 | -4% | -$39,319 | ||||||
| M | 2025-04-14 | PROK | Prokidney Corp. | Control Empresarial De Capitales S.A. De C.V. | Add'l Rep. Persons-see Ex.99-1, 10% | P - Purchase | $0.71 | +736,105 | 73,330,330 | +1% | +$520,599 | |||||
2025-04-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $106.40 | -2,500 | 168,174 | -1% | -$266,000 | ||||||
2025-04-11 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $1.90 | +2,400 | 325,087 | +1% | +$4,560 | ||||||
2025-04-14 | HUMA | Humacyte, Inc. | Scheessele William John | Chief Commercial Officer | P - Purchase | $1.54 | +6,493 | 22,018 | +42% | +$9,999 | ||||||
| M | 2025-04-10 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.01 | +600 | 112,620 | +1% | +$1,206 | |||||
2025-04-10 | XTNT | Xtant Medical Holdings, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $0.42 | -73,114,592 | 0 | -100% | -$30,708,129 | ||||||
| M | 2025-04-10 | PROK | Prokidney Corp. | Control Empresarial De Capitales S.A. De C.V. | Add'l Rep. Persons-see Ex.99-1, 10% | P - Purchase | $0.61 | +1,034,118 | 72,594,225 | +1% | +$628,847 | |||||
2025-04-10 | HUMA | Humacyte, Inc. | Sander Dale A. | CFO, Chief Corp. Deve. Officer | P - Purchase | $1.53 | +20,000 | 42,600 | +88% | +$30,600 | ||||||
2025-04-10 | HUMA | Humacyte, Inc. | Parikh Shamik J | Chief Medical Officer | P - Purchase | $1.55 | +7,500 | 7,500 | New | +$11,625 | ||||||
2025-04-09 | CMPX | Compass Therapeutics, Inc. | Gordon Carl L | Dir, 10% | S - Sale | $1.59 | -3,571,428 | 15,219,994 | -19% | -$5,678,571 | ||||||
2025-04-09 | CMPX | Compass Therapeutics, Inc. | Orbimed Advisors LLC | Dir, 10% | S - Sale | $1.59 | -3,571,428 | 15,219,994 | -19% | -$5,678,571 | ||||||
| M | 2025-04-09 | TECX | Tectonic Therapeutic, Inc. | Springer Timothy A | Dir, 10% | P - Purchase | $16.20 | +141,923 | 6,024,338 | +2% | +$2,299,015 | |||||
| DM | 2025-04-09 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $41.50 | -49,700 | 260,354 | -16% | -$2,062,550 | |||||
2025-04-09 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $12.99 | -28,094 | 1,186,512 | -2% | -$364,941 | ||||||
2025-04-08 | ZIVO | Zivo Bioscience, Inc. | Maggiore Christopher D. | Dir, 10% | S - Sale | $16.25 | -20 | 507,000 | 0% | -$325 | ||||||
2025-04-07 | TECX | Tectonic Therapeutic, Inc. | Springer Timothy A | Dir, 10% | P - Purchase | $17.10 | +500,000 | 5,882,415 | +9% | +$8,550,000 | ||||||
2025-04-08 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale | $5.34 | -47,500 | 1,408,983 | -3% | -$253,650 | ||||||
| D | 2025-04-08 | ACLX | Arcellx, Inc. | Patel Kavita | Dir | S - Sale+OE | $57.50 | -1,500 | 0 | -100% | -$86,250 | |||||
2025-04-03 | CRGX | Cargo Therapeutics, Inc. | Radhakrishnan Anup | See Remarks | S - Sale | $4.00 | -1,629 | 77,317 | -2% | -$6,522 | ||||||
2025-04-07 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.96 | +500 | 112,020 | 0% | +$980 | ||||||
2025-04-08 | HUMA | Humacyte, Inc. | Sebelius Kathleen | Dir | P - Purchase | $1.32 | +50,000 | 91,207 | +121% | +$66,000 | ||||||
2025-04-08 | HUMA | Humacyte, Inc. | Green Charles Bruce | Dir | P - Purchase | $1.29 | +6,000 | 8,400 | +250% | +$7,740 | ||||||
2025-04-07 | HUMA | Humacyte, Inc. | Constantino Michael T. | Dir | P - Purchase | $1.26 | +16,000 | 32,950 | +94% | +$20,160 | ||||||
2025-04-07 | CMPX | Compass Therapeutics, Inc. | Anderman Jonathan | GC, Corporate Sec | P - Purchase | $1.54 | +20,000 | 21,000 | >999% | +$30,800 | ||||||
2025-04-07 | CMPX | Compass Therapeutics, Inc. | Lerner Neil | CHIEF ACCOUNTING OFFICER | P - Purchase | $1.42 | +20,000 | 320,000 | +7% | +$28,400 | ||||||
2025-04-04 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.04 | +800 | 111,520 | +1% | +$1,632 | ||||||
2025-04-07 | TECX | Tectonic Therapeutic, Inc. | McGuire Terrance | Dir | S - Sale | $17.10 | -500,000 | 657,976 | -43% | -$8,550,000 | ||||||
| M | 2025-04-03 | ZEOX | Zeo Scientifix, Inc. | Skycrest Holdings, LLC | Former 10% Owner | P - Purchase | $2.51 | +5,000 | 322,687 | +2% | +$12,550 | |||||
2025-04-04 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.06 | +41,000 | 1,899,029 | +2% | +$2,583 | ||||||
2025-04-02 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $36.22 | -3,860 | 247,173 | -2% | -$139,801 | ||||||
2025-04-04 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $5.25 | -10,000 | 61,156 | -14% | -$52,500 | ||||||
2025-04-04 | AIM | Aim Immunotech Inc. | Rodino Peter W III | COO, Secretary, Gen. Counsel | P - Purchase | $0.09 | +500 | 401,762 | 0% | +$44 | ||||||
| M | 2025-04-02 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.21 | +1,100 | 110,720 | +1% | +$2,435 | |||||
2025-04-03 | VIR | Vir Biotechnology, Inc. | De Backer Marianne | CEO | S - Sale | $5.95 | -79,712 | 822,623 | -9% | -$474,239 | ||||||
2025-04-02 | VYGR | Voyager Therapeutics, Inc. | Ferguson Toby | Chief Medical Officer | S - Sale | $3.43 | -10,086 | 157,914 | -6% | -$34,595 | ||||||
2025-04-02 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Pres, CEO | S - Sale | $3.43 | -10,885 | 430,931 | -2% | -$37,336 | ||||||
2025-04-02 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $38.73 | -124 | 111,538 | 0% | -$4,803 | ||||||
2025-04-02 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $38.73 | -206 | 267,518 | 0% | -$7,979 | ||||||
2025-04-02 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $38.73 | -140 | 130,481 | 0% | -$5,423 | ||||||
| D | 2025-04-02 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $38.73 | -492 | 660,474 | 0% | -$19,057 | |||||
2025-01-22 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $17.53 | +10,080 | 554,626 | +2% | +$176,682 | ||||||
2025-04-01 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $18.35 | -5,674 | 117,294 | -5% | -$104,122 | ||||||
2025-04-01 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale | $18.35 | -30,663 | 1,089,249 | -3% | -$562,684 | ||||||
2025-04-01 | BEAM | Beam Therapeutics Inc. | Ciaramella Giuseppe | Pres | S - Sale | $18.35 | -7,434 | 190,216 | -4% | -$136,418 | ||||||
2025-04-01 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $18.35 | -3,015 | 44,512 | -6% | -$55,330 | ||||||
| M | 2025-04-01 | BEAM | Beam Therapeutics Inc. | Simon Amy | Chief Medical Officer | S - Sale | $17.92 | -30,563 | 65,742 | -32% | -$547,835 | |||||
2025-04-03 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $2.24 | +1,200 | 109,620 | +1% | +$2,688 | ||||||
| M | 2025-03-31 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | P - Purchase | $4.23 | +34,775 | 5,641,643 | +1% | +$147,076 | |||||
2025-04-01 | HALO | Halozyme Therapeutics, Inc. | Henderson Jeffrey William | Dir | S - Sale | $64.05 | -503 | 33,108 | -1% | -$32,217 | ||||||
2025-03-27 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $2.84 | -986 | 615,052 | 0% | -$2,800 | ||||||
2025-03-27 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $2.84 | -247 | 402,184 | 0% | -$701 | ||||||
2025-03-27 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $2.84 | -4,864 | 374,567 | -1% | -$13,814 | ||||||
2025-03-27 | RLAY | Relay Therapeutics, Inc. | Adams Brian | GC | S - Sale | $2.84 | -298 | 405,972 | 0% | -$846 | ||||||
| D | 2025-03-26 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $11.60 | +1,034,482 | 1,844,570 | +128% | +$11,999,991 | |||||
| D | 2025-03-27 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $6.04 | -138,574 | 1,117,450 | -11% | -$836,987 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |